Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 6Sarcoma 2Gynecologic 2Genitourinary 2Endocrine 2NET 1Head & Neck 1Dermatologic 1CNS 1Breast 1

Conditions

Breast Neoplasms 349Triple Negative Breast Neoplasms 59Ovarian Neoplasms 43Colorectal Neoplasms 34Prostatic Neoplasms 32Carcinoma, Non-Small-Cell Lung 25Neoplasms 24Endometrial Neoplasms 23Neoplasm Metastasis 19Lung Neoplasms 17Uterine Cervical Neoplasms 16Stomach Neoplasms 16Melanoma 16Squamous Cell Carcinoma of Head and Neck 15Pancreatic Neoplasms 15Carcinoma, Renal Cell 14Urinary Bladder Neoplasms 12Head and Neck Neoplasms 11Sarcoma 10Esophageal Neoplasms 10Small Cell Lung Carcinoma 8Colonic Neoplasms 8Kidney Neoplasms 7Advanced Breast Cancer 7Liver Neoplasms 6Cholangiocarcinoma 6Carcinoma, Transitional Cell 6Carcinoma, Hepatocellular 6Brain Neoplasms 6Anatomic Stage I Breast Cancer AJCC v8 6

Interventions

tivozanib 1atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bile Duct Neoplasms × Breast × 30 days × Clear all
NCT05000294 2026-06-05

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

University of Florida

Phase 1/2 Recruiting
29 enrolled
BreastEndocrineGastrointestinalGenitourinaryGynecologicNETSarcoma

Bile Duct Neoplasms, Breast Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vulvar Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡